Find Clinical Trials | Cedars-Sinai

395 results found

Leukemia, not otherwise specified

Ziftomenib in Combination With Nonintensive or Intensive Therapy in Acute Myeloid Leukemia

This study focuses on people with acute myeloid leukemia (AML) and consists of 2 independent studies/ treatment regimens. AML is a type of blood cancer in which infection-fighting cells (white blood cells) do not mature ...

Breast

Alliance, A012303, Ph3, Randomized, Br Cancer, trastuzumab +/- N D Pertuzumab

Primary Objective: To evaluate whether 6 months of combined neo/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast ...

Unknown Sites

Avenzo Therapeutics, AVZO-1418-1001, Ph 1/2, open label, AVZO-1418, solid tumors

Primary Objective: Phase 1 Dose Escalation: 1. To determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) of AVZO-1418 as monotherapy and in combination therapy 2. To characterize the safety and tolerability of AVZO-1418 ...

Breast, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, Other Female Genital ...

Corcept Therapeutics, CORT125236-750, Ph 1b/2, Nenocorilant in Combo w Nivo, Adv Solid Malignancies

Dose-Finding Phase 1b - Part 1 Primary Objectives: To evaluate the safety and tolerability of nenocorilant in combination with nivolumab in patients with advanced solid malignancies. To determine the maximum tolerated dose (MTD) and/or the ...

Colon

CSMC, IIT2022-11-Gangi-SAMe, Ph2, Open-label, S-Adenosylmethionine (SAMe), Colorectal Cancer.

Primary Objective 1 To identify the effect of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver predominant stage IV colorectal cancer. Secondary Objectives 1 To estimate the Objective ...